Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04006301 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04006301 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 10 participants.
The verdict
NCT04006301, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JNJ-74699157 in participants with advanced solid tumors harboring a kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation (Part 1: Dose escalation) and to determine the safety and preliminary antitumor activity of JNJ-74699157 at the RP2D regimen in participants with advanced solid tumors harboring a KRAS G12C mutation (Part 2: Dose expansion).
Interventions
- DRUG JNJ-74699157
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-07-26 |
| Est. Completion | 2020-07-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04006301
The ClinicalTrials.gov registry entry for NCT04006301 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JNJ-74699157 is the first listed.
NCT04006301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04006301 about?
NCT04006301 is a clinical study titled "First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation". The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JNJ-74699157 in participants with advanced solid tumors harboring a kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation (Part 1: Dose escalation) and to determin...
What is the current status of trial NCT04006301?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-07-26. Estimated completion is 2020-07-13.
What interventions are being tested in trial NCT04006301?
The interventions under investigation include: JNJ-74699157 (DRUG).
Who is sponsoring clinical trial NCT04006301?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.